STI Stock Trade Intelligence
NOX

NOXOPHARM LIMITED

Health Care · ASX:NOX
$0.0370
0.00%
Market cap
$12M
Turnover
$4,781
Last price
$0.0370
Day change
0.00%
Announcements
19
Range, past year
Open 0.099 · Low 0.032 · Now 0.037 · High 0.135
Open NOX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

NOX momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
42/100
Wyckoff phase
Downtrend9d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
+5.7%
1 Month
-26.0%
1 Year
-58.9%
RSI
28
Avg daily range
7.9%

NOXOPHARM LIMITED scores 42 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 9 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.91 — highly linear uptrend
  • Volume 1.7× 60-day avg
Points to watch
  • RSI oversold (28)
  • 60d drawdown -63.2%
  • High volatility (ATR 7.9%)
  • Thin liquidity
  • Risk rating: Very High
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

NOX announcements

Recent price-sensitive releases.
  • 2026-11-12 Noxopharm receives $1.4 million R&D tax incentive rebate Periodic Reports - Other
  • 2026-10-29 Voluntary Suspension Suspension from Official Quotation
  • 2026-10-27 Trading Halt Trading Halt
  • 2026-09-01 Novel oligonucleotides data presented at Options Conference Progress Report
  • 2026-08-28 Appendix 4E - Preliminary Financial Report Preliminary Final Report
  • 2026-08-26 New preclinical data supports immuno-oncology approach Progress Report
  • 2026-07-22 Quarterly Activities/Appendix 4C Cash Flow Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.